A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Patkar, Ashwin ^a   Gilmer, William ^b   Pae, Chi un ^a   Vöhringer, Paul A ^c,d,h   Ziffra, Michael ^b   Pirok, Edward ^b   Mulligan, Molly ^b   Filkowski, Megan M ^e   Whitham, Elizabeth A ^c   Holtzman, Niki S ^c   Thommi, Sairah B ^c   Logvinenko, Tanya ^c   Loebel, Antony ^f   Masand, Prakash ^a   Ghaemi, S Nassir ^c,g  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHILE   (Chile)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; PLACEBO; ZIPRASIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AKATHISIA; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR II DISORDER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIGRAINE; MIXED MANIA AND DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; BIPOLAR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 84860126120     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034757     Document Type: Article

References (22)

1. Salvatore P, Baldessarini RJ, Centorrino F, Egli S, Albert M, et al. (2002) Weygandt's On the Mixed States of Manic-Depressive Insanity: a translation and commentary on its significance in the evolution of the concept of bipolar disorder. Harv Rev Psychiatry 10: 255-275.
2. Trede K, Salvatore P, Baethge C, Gerhard A, Maggini C, et al. (2005) Manic-depressive illness: evolution in Kraepelin's Textbook, 1883-1926. Harv Rev Psychiatry 13: 155-178.
3. Dunner D, (1998) Diagnostic revisions for DSM-IV. In: Goodnick P, editors. Mania: Clinical and research perspectives Washington DC American Psychiatric Press pp. 3-10.
4. McElroy SL, Keck PE, Pope HG, Hudson JI, Faedda GL, et al. (1992) Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry 149: 1633-1644.
5. Swann AC, (2000) Depression, mania, and feeling bad: the role of dysphoria in mixed states. Bipolar Disord 2: 325-327.
6. Akiskal HS, Benazzi F, (2004) Validating Kraepelin's two types of depressive mixed states: "depression with flight of ideas" and "excited depression". World J Biol Psychiatry 5: 107-113.
7. Benazzi F, (2001) Depressive mixed state: testing different definitions. Psychiatry Clin Neurosci 55: 647-652.
8. Koukopoulos A, Koukopoulos A, (1999) Agitated depression as a mixed state and the problem of melancholia. Psychiatr Clin North Am 22: 547-564.
9. Perugi G, Akiskal HS, Micheli C, Musetti L, Paiano A, et al. (1997) Clinical subtypes of bipolar mixed states: validating a broader European definition in 143 cases. J Affect Disord 43: 169-180.
10. First M, Spitzer, RL, Gibbon, M, Williams, JBW, (1995) Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID I-P, Version 2.0). New York Biometrics Research Department, New York State Psychiatric Institute.
11. Galinowski A, Lehert P, (1995) Structural validity of MADRS during antidepressant treatment. Int Clin Psychopharmacol 10: 157-161.
12. Young RC, Biggs JT, Ziegler VE, Meyer DA, (1978) A rating scale for mania: Reliability, validity, and sensitivity. Br J Psychiatry 133: 429-435.
13. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W, (1997) Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Research 73: 159-171.
14. Jones SH, Thornicroft G, Coffey M, Dunn G, (1995) A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 166: 654-659.
15. Barnes TR, (2003) The Barnes Akathisia Rating Scale-revisited. J Psychopharmacol 17: 365-370.
16. Simpson GM, Angus JWS, (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (Suppl 212): 11-19.
17. Goodwin F, Jamison K, (2007) Manic Depressive Illness, 2nd edition. New York Oxford University Press.
18. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, et al. (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275: 101-113.
19. Sachs G, Ice K, Chappell P, Schwartz J, Gurtovaya O, et al. (2010) (In press)) Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder Journal of Clinical Psychiatry.
20. Sachs G, Lombardo I, Yang R, Kremer C. Lessons From the Ziprasidone Bipolar Depression Program; 2009 Jun 29-Jul 2, 2009; Hollywood, FL.
21. Benazzi F, (2008) Reviewing the diagnostic validity and utility of mixed depression (depressive mixed states). Eur Psychiatry 23: 40-48.
22. Cassano GB, Rucci P, Frank E, Fagiolini A, Dell'Osso L, et al. (2004) The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. Am J Psychiatry 161: 1264-1269.